Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
Glucosamine as a regulator of O-GlcNAc signaling: linking metabolism to disease pathogenesis.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kim Sang-Min, Lee Chanhaeng, Kim Dong Yeol, Han Inn-Oc
Аннотация
BACKGROUND: Glucosamine, a naturally occurring amino sugar abundant in cartilage, has long been utilized as a dietary supplement to alleviate osteoarthritis (OA) and joint pain. Beyond its structural role in maintaining joint integrity, glucosamine is metabolized through the hexosamine biosynthetic pathway (HBP) to generate UDP-N-acetylglucosamine (UDP-GlcNAc), the indispensable donor substrate for protein O-linked N-acetylglucosamine (O-GlcNAc) modification.
FINDINGS: Accumulating evidence indicates that glucosamine-driven modulation of HBP flux and the consequent alteration of O-GlcNAcylation exert profound effects on cellular signaling, metabolic regulation, and inflammatory responses. These mechanisms extend far beyond musculoskeletal health, influencing the pathogenesis of diverse conditions such as rheumatoid arthritis (RA), diabetes, obesity, neuroinflammation, neurodegenerative disorders, sepsis, and cancer. Despite glucosamine's long-standing clinical use, its potential role as a metabolic regulator of O-GlcNAc cycling remains underexplored.
CONCLUSION: This review integrates current insights into the molecular basis of glucosamine-enhanced O-GlcNAcylation, highlighting its implications for disease onset and progression, and proposing a broader therapeutic framework that positions glucosamine as a promising modulator of inflammation and systemic pathology.
FINDINGS: Accumulating evidence indicates that glucosamine-driven modulation of HBP flux and the consequent alteration of O-GlcNAcylation exert profound effects on cellular signaling, metabolic regulation, and inflammatory responses. These mechanisms extend far beyond musculoskeletal health, influencing the pathogenesis of diverse conditions such as rheumatoid arthritis (RA), diabetes, obesity, neuroinflammation, neurodegenerative disorders, sepsis, and cancer. Despite glucosamine's long-standing clinical use, its potential role as a metabolic regulator of O-GlcNAc cycling remains underexplored.
CONCLUSION: This review integrates current insights into the molecular basis of glucosamine-enhanced O-GlcNAcylation, highlighting its implications for disease onset and progression, and proposing a broader therapeutic framework that positions glucosamine as a promising modulator of inflammation and systemic pathology.